| Stereochemistry | RACEMIC |
| Molecular Formula | C12H14N2O3 |
| Molecular Weight | 234.2512 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=CC=CC=C2C(=O)N1CC(O)CO
InChI
InChIKey=NTGLQWGMESPVBV-UHFFFAOYSA-N
InChI=1S/C12H14N2O3/c1-8-13-11-5-3-2-4-10(11)12(17)14(8)6-9(16)7-15/h2-5,9,15-16H,6-7H2,1H3
| Molecular Formula | C12H14N2O3 |
| Molecular Weight | 234.2512 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Diproqualone was used primarily for the treatment of inflammatory pain associated with osteoarthritis. The analgesic activity of diproqualoneis synergistic with that of noramidopyrine. It also display anti-inflammatory action in the rat, inhibiting plantar edema with dextran or serotonin, atopic edema from ovalbumin, etc. It has spasmolytic, anticholinergic and antihistaminic action in higher doses. It is not hypnotic and has no anticonvulsant effects. The therapeutic symptoms for diproqualone are all types of pain: postoperative, posttraumatic, dental, neuritis, anti-inflammatory arthritis, etc.
